Contact your GP if heartburn occurs more than twice weekly despite lifestyle changes, or if you experience difficulty swallowing, persistent vomiting, or unintentional weight loss
This leads to the condition of being overweight or obese
We need to go slow and make sure that you don't have any problems such as low blood sugar. Resources We Trust New Analysis Examines Long-Term Outcomes of GLP-1 Therapies in Type 1 Diabetes Cleveland Clinic: Mayo Clinic: Weigh Benefits, Risks Carefully Before Taking Off-Label Medication T1D Exchange: Understanding Off-Label Use of GLP-1 (Glucagon-Like Peptide-1 Receptor) Agonists Among Providers Participating in the T1D Exchange Quality Improvement Collaborative (T1DX-QI) SGLT2 Inhibitors in Type 1 Diabetes Where Do We Stand in 2025
Tirzepatide is a dual GIP/GLP-1 receptor agonist found in Zepbound and Mounjaro
This method reduces side effects and allows for more gradual progress
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial